CAS: 1780-26-3; 2-Methyl-4,6-Dichloropyrimidine

相似化合物

4994-86-9 1451391-83-5 1195-34-2

上下游产品

2-methyl-1H-pyrimidine-4,6-dione 2-methyl-4,6-dihydroxypyrimidine 2-methyl-4,6-dimethoxypyrimidine (6-chloro-2-methyl-pyrimidin-4-yl)-(4-chloro-phenyl)-amine 6-chloro-2-methyl-N-(4-nitrophenyl)pyrimidin-4-amine N4,N4,N6,N6-pentamethyl-pyrimidine-4,6-diyldiamine2,N4,N4,N6,N6-pentamethyl-pyrimidine-4,6-diyldiamine

2-甲基-4,6-二羟基嘧啶置于三氯氧磷体系中,化学反应 3.0H,以58%的收率获得4,6-二氯-2-甲基嘧啶
参考文献:甲基和硫甲基取代的嘧啶作为促肾上腺皮质激素释放激素1型拮抗剂的合成,分子模型和生物学活性.
标题:甲基和硫甲基取代的嘧啶作为促肾上腺皮质激素释放激素1型拮抗剂的合成,分子模型和生物学活性.
摘要:以中等到非常好的收率合成了四个小的,差异取代的氨基嘧啶的靶向库.在c2 / C4处观测到出色的区域化学取代作用,选择性> 50:1.筛选所有类似物与crh1和crh2受体相互作用的能力.在所有情况下,在crh2处仅观测到不良的激动和/或拮抗行为.但是,有几种化合物是有效的和选择性的crh1拮抗剂,最值得注意的是13A Ki = 39 Nm.另外,我们利用了这些数据以及其他人最近报告的数据来完善我们原始的crh1药效团(j Med.Chem.,1999,42,2351-2357).
Doi:10.1039/b305458F

专利信息

专利号:US-2023399302-A1
优先权日:2020-10-29
标题:Process for the preparation of heteroaryl-substituted sulfur(vi) compounds
发明人：LOPCHUK JUSTIN M; SHULTZ ZACHARY P; SCATTOLIN THOMAS
权利人:H LEE MOFFITT CANCER CT & RES
摘要:The present disclosure provides processes for the synthesis of organic compounds, in particular processes for the synthesis of heteroaryl-substituted sulfur(VI) compounds by nucleophilic aromatic substitution.

专利号:US-6608199-B2
优先权日:2000-07-07
标题 :Synthesis of chlorinated pyrimidines
发明人：DOYLE TIMOTHY JOHN; BENKE ALAN HENRY; WEHRENBERG PETER KARL; NADY LOUIE AKOS
权利人:SYNGENTA LTD
摘要:The invention provides a process for synthesizing chlorinated pyrimidines. The process includes reacting imidoyl chloride compounds with phosgene (COCl2). The imidoyl chloride compounds can be supplied as starting materials or can be produced by reacting organic amides with phosgene or reacting organic nitrites with hydrogen chloride. The chlorinated pyrimidines, such as 4,6-dichloropyrimidine, can be used to synthesize other compounds useful in a variety of compositions, such as fungicides, pesticides, and pharmaceuticals.

专利号:US-9115124-B1
优先权日:2014-03-11
标题 :Process and intermediates for the preparation of dasatinib
发明人：BARUTO ALESSANDRO; GABOARDI MAURO; CASTALDI MARTA; CASTALDI GRAZIANO
权利人:CERBIOS PHARMA SA
摘要:The present invention relates to a process for the synthesis of dasatinib and to intermediates useful for its preparation.

专利号:US-6982331-B2
优先权日:2001-06-08
标 题 :Synthesis of chlorinated pyrimidines
发明人：DOYLE TIMOTHY J; BENKE ALAN H; WEHRENBERG PETER K; NADY LOUIE A; RODRIGUEZ GILBERT
权利人:SYNGENTA CROP PROT INC
摘要:The invention provides a process for synthesizing chlorinated pyrimidines. The process includes reacting imidoyl chloride compounds with phosgene (COCl 2 ). The imidoyl chloride compounds can be supplied as starting materials or can be produced by reacting organic amides with phosgene or reacting organic nitrites with hydrogen chloride. Phosgene may be replaced by equivalent reagents. The chlorinated pyrimidines, such as 4,6-dichloropyrimidine, can be used to synthesize other compounds useful in a variety of compositions, such as fungicides, pesticides, and pharmaceuticals.

专利号:WO-2011095125-A1
优先权日:2010-02-02
标 题:Synthesis methods and purification methods of dasatinib
发明人：YAN RONG; YANG HAO; HOU WEN; XU YONGXIANG
权利人:NAN JING CAVENDISH BIO ENGINEERING TECHNOLOGY CO LTD; YAN RONG; YANG HAO; HOU WEN; XU YONGXIANG
摘要:Synthesis methods of dasatinib are provided, which comprise the following steps: reacting a compound of formula I with a compound of formula II to obtain a compound of formula III, and then connecting the compound of formula III with 2-chloro-6-methylaniline and 1-(2-hydroxyethyl)piperazine in any order to give dasatinib. Furthermore, purification methods of dasatinib are also provided.

专利号:US-9108954-B2
优先权日:2010-02-02
标 题:Synthesis process of dasatinib and intermediate thereof
发明人：YAN RONG; YANG HAO; HOU WEN; XU YONGXIANG
权利人:YAN RONG; YANG HAO; HOU WEN; XU YONGXIANG; NAN JING CAVENDISH BIO ENGINEERING TECHNOLOGY CO LTD
摘要:Synthesis process of dasatinib is disclosed, which includes the step of reacting the compound of formula I with that of formula II to obtain the compound of formula III. Also disclosed is the compound of formula III which is used as an intermediate for synthesizing dasatinib. The substituents of R1, R2, R3 or R4 in formulae I, II or III are defined as in the description.